Articles Tagged With: cidp
-
Long-Term Outcome for Patients with CIDP
In a careful meta-analysis of published series of treated patients with chronic inflammatory demyelinating polyneuropathy (CIDP), about one-half of patients achieved a good long-term remission with independent function and only about 8% were unable to walk independently.
-
What Is the Right Dose of Immunoglobulin to Treat CIDP?
In this comparative trial of different doses of intravenous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy, higher doses appeared to result in a higher percentage of patients who improved. However, there was no control group and there were many confounding issues that make it difficult to reach a definitive conclusion around optimal dosing.
-
Intravenous Immunoglobulin for Stable CIDP: Stop or Taper?
First-line therapy for chronic inflammatory demyelinating polyneuropathy is intravenous immunoglobulin (IVIG), but the timing and method for withdrawal of this treatment are uncertain. In a retrospective review of stable patients on IVIG, investigators at the National Hospital in London observed that there was no significant difference in the likelihood of deterioration or response to retreatment if IVIG was stopped abruptly or tapered slowly.
-
What Is Focal CIDP?
Chronic inflammatory demyelinating polyneuropathy (CIDP) usually is diagnosed in patients who have a generalized disorder. However, there are focal syndromes that have been observed and diagnosed under different names that meet many of the clinical and electrodiagnostic criteria of CIDP and may be referred to as “focal” CIDP.
-
Is it Chronic Inflammatory Demyelinating Polyneuropathy or Charcot-Marie-Tooth Disease?
Charcot-Marie-Tooth disease may be confused with chronic inflammatory demyelinating polyneuropathy, resulting in inappropriate and hazardous treatments. Age at onset < 40 years, a family history of neuropathy, absence of nerve hypertrophy on magnetic resonance imaging, and poor response to intravenous immune globulin treatment should prompt a genetic evaluation.
-
Genetic Biomarkers of Immunoglobulin Response in Patients with CIDP
Nearly 25% of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) have a poor response to intravenous immunoglobulin treatment. Variations in the PRF1 and FCGR2B genes in CIDP patients offer insights into the heterogenous treatment response.
-
Pitfalls in the Diagnosis of CIDP
Chronic inflammatory demyelinating polyradiculoneuropathy is commonly misdiagnosed. It is important to adhere to established diagnostic criteria and to regularly re-evaluate all patients given this diagnosis.
-
Cranial Neuropathy in CIDP
Cranial nerves are infrequently involved in typical chronic inflammatory demyelinating polyneuropathy, but involvement is more common in multifocal acquired demyelinating sensory and motor neuropathy (about 50%). The facial nerve is the most commonly affected cranial nerve, often bilateral.
-
Lifestyle and Environmental Risk Factors for Chronic Inflammatory Demyelinating Polyradiculoneuropathy
In a large Italian database-derived, case-control study of dietary and environmental factors, antecedent infections and diet appeared to influence the onset and course of chronic inflammatory demyelinating polyradiculoneuropathy. The diagnosis and treatment of this disorder remain a challenge.
-
MRI of the Brachial and Lumbar Plexus Assists in the Diagnosis of CIDP
MRI of the brachial plexus and/or lumbar plexus may be helpful in making a diagnosis of chronic inflammatory demyelinating polyradiculopathy in patients who do not meet the standard criteria. Imaging findings include increased signal intensity, nerve hypertrophy, and nerve contrast enhancement.